^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Herceptin (trastuzumab)

i
Other names: R 597, R597, RG597, RG-597, R-597, RG 597
Company:
Roche
Drug class:
HER2 inhibitor
Related drugs:
1d
DLL4-targeted CAR-T therapy sensitizes neoadjuvant chemotherapy via eliminating cancer stem cells and reshaping immune microenvironment in HER2+ breast cancer. (PubMed, J Immunother Cancer)
Our study revealed novel functions of DLL4 in cell stemness and immune infiltration, including NET formation and T cell exclusion, which collectively contributed to THP neoadjuvant therapy resistance in HER2+ BC. Furthermore, we provided a CAR-T-based therapy to sensitize the THP neoadjuvant therapy.
Journal • Cancer stem • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2)
|
Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab)
1d
Trastuzumab Potentiates Antitumor Activity of Thiopyrano[2,3-d]Thiazole Derivative in AGS Gastric Cancer Cells. (PubMed, Molecules)
Additionally, a significant increase in p53 protein levels and modulation of interleukin levels, including a marked reduction in IL-6 levels, were observed, suggesting an impact on apoptotic and inflammatory responses. These findings indicate that the combined use of LES-6400 and trastuzumab is a promising therapeutic strategy for gastric cancer, warranting further investigation into the mechanisms of action and potential clinical applications of this combined approach.
Journal
|
IL6 (Interleukin 6) • ANXA5 (Annexin A5)
|
IL5 elevation
|
Herceptin (trastuzumab)
2d
Cost-Effectiveness Analysis of Adjuvant Pertuzumab and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer in Japan. (PubMed, Clin Drug Investig)
The economic viability of dual HER2-targeted therapy was most pronounced in patients with node-positive high-risk early breast cancer. This study highlights the potential of dual HER2-targeted therapy as a cost-effective addition for these cases.
Journal • HEOR • Cost-effectiveness • Cost effectiveness
|
HER-2 (Human epidermal growth factor receptor 2)
|
EGFR positive
|
Herceptin (trastuzumab) • Perjeta (pertuzumab)
2d
The addition of PD-1 inhibitor overcame trastuzumab resistance in patients with HER2 positive, PD-L1 negative metastatic gastric cancer: Case report and review of literature. (PubMed, Front Pharmacol)
His resistance to trastuzumab was overcome after the addition of a PD-1 inhibitor, after which he received a durable response for more than 8 months. In HER2-positive, PD-L1-negative metastatic GC, the addition of PD-1 inhibitors after first-line chemotherapy and trastuzumab treatment resistance may be an option.
Review • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • HER-2 positive • PD-L1 negative
|
Herceptin (trastuzumab)
3d
Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay. (PubMed, Methods Cell Biol)
However, in several instances, it was found that 2D cultures were poorly sensitive, even to powerful monoclonal antibodies like trastuzumab, whereas three-dimensional (3D) cultures may better reveal the tumor-inhibitory activity of circulating antibodies. We describe here a breast cancer 3D soft agar colony growth inhibition assay that was developed to quantify the tumor cell inhibitory activity of antibodies against human HER-2 elicited in mice by specific vaccines. The assay might be readily modified to analyze antibodies against different surface antigens expressed by other tumor types and also for testing of new monoclonal antibodies and nanobodies.
Journal • Tumor cell
|
HER-2 (Human epidermal growth factor receptor 2)
|
Herceptin (trastuzumab)
3d
Trastuzumab plus chemotherapy versus chemotherapy alone in HER2-positive gastric cancer treatment in Iran: a cost-effectiveness analysis. (PubMed, Health Econ Rev)
The addition of trastuzumab to chemotherapy regimens improved clinical outcomes in HER2-positive gastric cancer patients. From an economic perspective, the CAPOX regimen is the most cost-effective option when considering a cost-effectiveness threshold of up to two times Iran's GDP per capita. However, when the threshold increases to three times the GDP per capita, the CAPOX + Trastuzumab regimen becomes the preferred choice. These findings provide valuable insights for healthcare policymakers in Iran.
Journal • HEOR • Cost-effectiveness • Cost effectiveness
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Herceptin (trastuzumab) • 5-fluorouracil • leucovorin calcium
3d
Inflammatory stress determines the need for chemotherapy in patients with HER2-positive esophagogastric adenocarcinoma receiving targeted and immunotherapy. (PubMed, Cancer Immunol Res)
Herein, we report extended follow-up data from the INTEGA trial (NCT03409848), which investigated the efficacy of the anti-PD-1 nivolumab, trastuzumab, and FOLFOX chemotherapy (FOLFOX arm) in comparison to a chemotherapy-free regimen involving nivolumab, trastuzumab, and the anti-CTLA-4 ipilimumab (Ipi arm) in the first-line setting for advanced disease...Furthermore, a low NLR characterized patients benefiting from immune- and targeted therapy without the need for additional chemotherapy. This data suggests that patient selection based on inflammatory stress-driven immune changes could help to customize first-line treatment in patients with advanced HER2-positive EGA to potentially improve long-term survival.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • IL6 (Interleukin 6)
|
HER-2 positive
|
Opdivo (nivolumab) • Herceptin (trastuzumab) • Yervoy (ipilimumab) • 5-fluorouracil • leucovorin calcium
3d
Enhancing antitumor activity of herceptin in HER2-positive breast cancer cells: a novel DNMT-1 inhibitor approach. (PubMed, Discov Oncol)
This upregulation, in turn, enhanced the cells' sensitivity to HER2 antagonists, indicating that DI-1's mechanism involves inhibiting DNMT-1's recruitment to PTEN's promoter region. Consequently, by increasing PTEN expression, DI-1 amplifies the sensitivity of HER2-positive breast cancer cells to treatment, suggesting its potential as a promising therapeutic strategy in this context.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • DNMT1 (DNA methyltransferase 1)
|
HER-2 positive • HER-2 amplification • PTEN expression • DNMT1 expression
|
Herceptin (trastuzumab)
4d
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma (clinicaltrials.gov)
P=N/A, N=28, Completed, NovoCure Ltd. | Unknown status --> Completed | Trial completion date: Sep 2021 --> Jun 2024 | Trial primary completion date: Sep 2021 --> Jun 2024
Trial completion • Trial completion date • Trial primary completion date
|
Herceptin (trastuzumab) • capecitabine • oxaliplatin
5d
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol (clinicaltrials.gov)
P2, N=220, Active, not recruiting, West German Study Group | Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Jan 2025 | Trial primary completion date: Aug 2015 --> Jan 2025
Enrollment closed • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
PGR negative
|
Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab)
6d
The Sagittarius Trial (clinicaltrials.gov)
P3, N=700, Recruiting, IFOM ETS - The AIRC Institute of Molecular Oncology | Not yet recruiting --> Recruiting
Enrollment open
|
Signatera™
|
Opdivo (nivolumab) • Herceptin (trastuzumab) • Yervoy (ipilimumab) • 5-fluorouracil • Vectibix (panitumumab) • Perjeta (pertuzumab) • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
6d
RENAISSANCE: Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (clinicaltrials.gov)
P3, N=183, Completed, Krankenhaus Nordwest | Active, not recruiting --> Completed | Trial completion date: Feb 2026 --> Aug 2024 | Trial primary completion date: Feb 2026 --> Aug 2024
Trial completion • Trial completion date • Trial primary completion date • HEOR • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • Herceptin (trastuzumab) • docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium
8d
New trial • Metastases
|
Herceptin (trastuzumab) • Zepsun (donafenib)
8d
Clinical observation on the intervention of trastuzumab-induced cardiotoxicity by adding and subtracting Chai Gui Long Mu Tang (ChiCTR2400089482)
P=N/A, N=60, Completed, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Longhua Hospital Affiliated to Shanghai University of Traditional
New trial
|
Herceptin (trastuzumab)
8d
New P4 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive
|
Herceptin (trastuzumab) • Irene (pyrotinib) • letrozole • AiRuiKang (dalpiciclib)
8d
The efficacy and safety of Trastuzumab combined with pyrotinib in neoadjuvant treatment for HER2-positive eraly breast cancer: A real-world study (ChiCTR2400090883)
P4, N=40, Not yet recruiting, Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College
New P4 trial • Real-world evidence • Real-world
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 amplification
|
Herceptin (trastuzumab) • Irene (pyrotinib)
8d
A study Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens (ChiCTR2400088975)
P1/2, N=35, Not yet recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
New P1/2 trial
|
HER-2 positive
|
Herceptin (trastuzumab) • Aidixi (disitamab vedotin)
10d
Trial completion
|
HER-2 positive • HER-2 negative • HER-2 negative + HR negative • HER-2 positive + HR negative
|
Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • cyclophosphamide • epirubicin
10d
Trial completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
12d
Factors Associated With Infusion Reactions in Patients With Breast Cancer Receiving Trastuzumab. (PubMed, Cancer Diagn Progn)
Multiple logistic regression analysis showed that pertuzumab (PER) use, high alkaline phosphatase (ALP), and low high-density lipoprotein (HDL) cholesterol levels were associated with IR. IR should be considered when PER is combined with TRA. ALP and HDL cholesterol levels may be predictive markers of TRA-induced IR in patients with breast cancer.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
Herceptin (trastuzumab) • Perjeta (pertuzumab)
13d
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases (clinicaltrials.gov)
P2, N=47, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)
|
HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 positive + HER-2 overexpression
|
Herceptin (trastuzumab) • paxalisib (GDC-0084)
14d
Evaluation of early cardiotoxicity in HER2-positive breast cancer patients receiving radiotherapy and concurrent trastuzumab. (PubMed, Ir J Med Sci)
In our study,it was found that not only trastuzumab but also taxane-based agents could be cardiotoxic. However, no connection was found between RT doses and the decrease in LVEF.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Herceptin (trastuzumab)
14d
Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer. (PubMed, World J Gastroenterol)
In the first-line treatment of HER2-positive advanced gastric cancer, inetetamab and trastuzumab showed comparable efficacy. The inetetamab group showed superior PFS, and both groups had good safety.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • EGFR positive
|
Herceptin (trastuzumab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • Cipterbin (inetetamab)
14d
Targeting erbB Pathways in Breast Cancer: Dual Kinase Inhibition for Brain Metastasis and Prevention of p185HER2/Neu Tumor Development. (PubMed, Breast Cancer (Dove Med Press))
The Herceptin-resistant breast cancer cell line JIMT-1 was used in an in vivo tumor model, and MMTV-erbB2 (Fo5) transgenic mice models were used to evaluate the efficacy and safety of ER121 as neoadjuvant. ER121 is a non-toxic small-molecule erbB kinase inhibitor and holds promise as an oral and systemic therapeutic agent for treating progressive erbB-driven tumors in therapeutic settings. Moreover, ER121 shows potential as a preventive therapy in neoadjuvant settings for erbB2-associated tumors and when administered systemically can dramatically limit erbB2 brain metastases in animal models.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR mutation • HER-2 overexpression • EGFR overexpression • EGFR overexpression + HER-2 overexpression
|
Herceptin (trastuzumab) • ER121
14d
Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC. (PubMed, J Pharm Anal)
Mechanistically, the augmented impact of XLLXF on NK cells is linked to a decrease in cytokine inducible Src homology 2 (SH2) containing protein (CISH) expression, which in turn activates the Janus kinase 1 (JAK1)/signal transducer and activator of transcription 5 (STAT5) pathway. Collectively, these findings suggested that XLLXF holds promise for enhancing NK cell function and sensitizing patients with HER2-positive BC to trastuzumab.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • JAK1 (Janus Kinase 1)
|
HER-2 positive • EGFR positive
|
Herceptin (trastuzumab)
15d
Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer. (PubMed, Med Oncol)
Further, CDK4/6 inhibitor can inhibit the proliferation of trastuzumab-resistant HER-2 positive breast cancer cells. Therefore, combination of CDK4/6 inhibitors and anti-HER2 targeted therapy may be an alternative and promising strategy to overcome trastuzumab resistance in the future.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CCND3 (Cyclin D3)
|
HER-2 positive
|
Herceptin (trastuzumab)
16d
Clinical • P3 data • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
HER2DX
|
Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab)
18d
Trastuzumab-Induced Early Corneal Melt in HER2-Positive Breast Cancer: A Case Report and Review. (PubMed, Am J Case Rep)
CONCLUSIONS Ocular adverse effects such as corneal epithelial changes and melts have been reported with trastuzumab. We recommend ophthalmology consultation for any ocular symptoms in patients on trastuzumab treatment.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • EGFR positive
|
Herceptin (trastuzumab)
19d
Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer. (PubMed, Case Rep Oncol)
Consequently, we determined that the patient presented with a condition similar to immune thrombocytopenic purpura (ITP) and selected a treatment approach consisting of eltrombopag, a thrombopoietin receptor agonist. Although uncommon, anti-HER2 antibodies can cause severe thrombocytopenia. Furthermore, if thrombocytopenia persists after treatment discontinuation and the administration of corticosteroids, exploring treatment options aligned with managing ITP is essential.
Journal • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • Promacta (eltrombopag)
19d
Vogt-Koyanagi-Harada-Like Uveitis Secondary to Pembrolizumab in Metastatic Gastric Cancer: A Case Report and Review of the Literature. (PubMed, Case Rep Oncol)
She continues on trastuzumab maintenance, and most recent imaging shows no evidence of disease. Oncologists should be aware of VKH-like disease as a possible immune-related adverse event and seek urgent ophthalmologic consultation when such symptoms arise.
Review • Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
HER-2 amplification • PD-L1 amplification
|
Keytruda (pembrolizumab) • Herceptin (trastuzumab) • 5-fluorouracil • leucovorin calcium
19d
Disitamab vedotin combined with apatinib in gastric cancer: A case report and review of literature. (PubMed, World J Clin Oncol)
Despite the unfavorable prognosis associated with advanced GC, the implementation of personalized treatment approaches may still prove beneficial for select patients. In patients with HER2-positive GC with extensive metastatic involvement, the use of the HER2-targeted combination with apatinib has demonstrated the potential to prolong both PFS and overall survival.
Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • HER-2 positive • MSI-H/dMMR • HER-2 overexpression • HER-2 amplification • HER-2 amplification + PD-L1 expression • HER-2 positive + HER-2 overexpression
|
Opdivo (nivolumab) • Herceptin (trastuzumab) • AiTan (rivoceranib) • Aidixi (disitamab vedotin) • anbenitamab (KN026)
19d
FCGR3A V158F gene polymorphism and trastuzumab response in HER2-positive breast cancer patients. (PubMed, Sci Rep)
V/V is associated with better treatment response and overall survival (OS) compared to F/V and F/F alleles. Assessment of FCGR3A-V158F gene polymorphism might be useful in making a treatment decision in HER2-positive breast cancer patients.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)
|
HER-2 positive • FCGR3A V158F
|
Herceptin (trastuzumab)
19d
[64Cu]Cu-NOTA-Trastuzumab and [89Zr]Zr-DFO-Trastuzumab in Xenografts with Varied HER2 Expression. (PubMed, Mol Pharm)
These findings underscore the potential of PET to monitor HER2 protein levels across heterogeneous tumors. Furthermore, our results suggest that further optimization of statin dosing and timing could offer a promising strategy to enhance trastuzumab accumulation in HER2-high, HER2-moderate, and HER2-low tumors.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
Herceptin (trastuzumab) • lovastatin
20d
Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab. (PubMed, NPJ Breast Cancer)
In those with RD, 36% lost HER2(+) status; IDFS events appeared similar in those with HER2(+) RD versus those with HER2(-) RD. The BM events seen in those with RD and pCR highlights the need for more effective therapy in NAST and adjuvant setting to minimize BM risk.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
Herceptin (trastuzumab) • Perjeta (pertuzumab)
20d
New trial • Circulating tumor DNA • Metastases
|
Signatera™
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)
21d
Anti-PD-L1 chimeric antigen receptor natural killer cell: Characterization and functional analysis. (PubMed, APMIS)
The degranulation assay demonstrated that CD107a frequencies between the PD-L1med and PD-L1high groups and between Herceptin-treated and non-treated groups were not statistically different...Regarding the efficient functional activity of PD-L1-CAR NK cells and the instinctive receptor balance-based response of NK cells, this observation could point to the inhibition of NK cell overactivation or even higher cytotoxicity and cytokine production rather than exhaustion, especially in the case of healthy NK cells. These findings can contribute to a better understanding of the potential and challenges of using primary NK cells for CAR-NK cell therapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
LAG3 (Lymphocyte Activating 3) • IL2RA (Interleukin 2 receptor, alpha) • LAMP1 (Lysosomal Associated Membrane Protein 1) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
|
PD-L1 expression
|
Herceptin (trastuzumab)
22d
LC-HRMS-based global metabolomics profiling unravels the distinct metabolic signature of lapatinib-resistant and trastuzumab-resistant HER2+ breast cancer cells. (PubMed, J Pharm Biomed Anal)
Joint pathway enrichment analysis of LAP-resistant DEMs and differentially expressed genes (DEGs) showed enrichment in glutathione metabolism, while that of TRZ-resistance and DEGs showed enrichment in carbohydrate metabolism, namely pentose and glucuronate interconversions, starch and sucrose metabolism, and galactose metabolism. The findings from this study indicate considerable metabolic changes in LAP- and TRZ-resistant HCC1954 cells, which are crucial for understanding the resistance mechanisms and developing strategies to overcome these problems.
Journal • Metabolomic study
|
HER-2 (Human epidermal growth factor receptor 2)
|
Herceptin (trastuzumab) • lapatinib
22d
De-Escalating Treatment Strategies for Patients with Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Early-Stage Breast Cancer. (PubMed, Cancers (Basel))
Though single-arm, the APT trial, in which patients with node-negative, small tumors received single-agent paclitaxel for 12 cycles plus trastuzumab for 1 year, was a practice-changing study. Several other recently published studies, like the PERSEPHONE trial, have shown more convincing data that 6 months of trastuzumab is not inferior to 12 months, in terms of disease-free survival (DFS), suggesting that de-escalating strategies with shorter treatment may be appropriate for some low-risk patients. Other de-escalating strategies involved an adaptive, response-directed approach, and personalized therapy that depends on tumor genomic profiling.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • EGFR positive • EGF expression
|
Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab)
24d
Nodal involvement in patients with small, clinically node-negative HER2-positive breast cancer after staging with FDG-PET/CT and neoadjuvant systemic therapy. (PubMed, Breast)
The proportion of patients with ypN + after NAST combined with FDG-PET/CT was only 6.1 %. Neoadjuvant treatment can be a safe treatment strategy for patients with stage I HER2+ BC.
Journal • FDG PET
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative
|
Herceptin (trastuzumab) • paclitaxel
25d
PI3K Mutation Profiles on Exons 9 (E545K and E542K) and 20 (H1047R) in Mexican Patients With HER-2 Overexpressed Breast Cancer and Its Relevance on Clinical-Pathological and Survival Biological Effects. (PubMed, Int J Breast Cancer)
Background: Trastuzumab resistance is associated with overexpressing the human epidermal growth factor receptor 2 (HER-2), which results from the altered phosphoinositide 3-kinase (PI3K) pathway in breast cancer patients...However, single and double-point mutations in PI3K were significantly associated with the clinical stages of diagnosis and tumor size (p = 0.027 and p = 0.04, respectively). Single and double-point mutations in PI3K are related to tumor size and advanced clinical-pathological traits in Mexican patients with HER-2 overexpression, and future molecular studies are necessary to understand these findings.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PI3K (Phosphoinositide 3-kinases)
|
HER-2 positive • HER-2 overexpression • PIK3CA H1047R • HER-2 positive + HER-2 overexpression
|
Herceptin (trastuzumab)
25d
Evaluation of Double Self-Immolative Linker-Based Antibody-Drug Conjugate FDA022-BB05 with Enhanced Therapeutic Potential. (PubMed, J Med Chem)
Utilizing this platform, FDA022-BB05 was successfully conjugated with the hydroxyl group-containing payload DXd using trastuzumab (FDA022) as the monoclonal antibody (mAb). Overall, these compelling findings support the promising therapeutic potential of FDA022-BB05, emphasizing the significance of diverse linker-payload platform strategies. This ADC is a valuable addition to targeted cancer therapy development, currently advancing through phase I clinical trials.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Herceptin (trastuzumab)
25d
A Study of IMU-131 (HER-Vaxx) in Combination with Chemotherapy or Pembrolizumab in Patients with Metastatic HER2/neu Over-Expressing Gastric Cancer (nextHERIZON) (clinicaltrials.gov)
P2, N=7, Completed, Imugene Limited | Active, not recruiting --> Completed | Trial completion date: Jul 2026 --> Apr 2024
Trial completion • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
PD-L1 expression • HER-2 overexpression • HER-2 expression
|
Keytruda (pembrolizumab) • Herceptin (trastuzumab) • paclitaxel • Cyramza (ramucirumab) • Her-VAXX